Antibiotics in sepsis

Intensive Care Medicine

Volumn 27, Issue 1, 2001, Pages

  Bochud, P Y ^a   Glauser, M P ^a   Calandra, T ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFLAMMATORY AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBENICILLIN; CEFAZOLIN; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; IMIPENEM; ISEPAMICIN; MEROPENEM; MEZLOCILLIN; MONOBACTAM DERIVATIVE; NETILMICIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SISOMICIN; TICARCILLIN; TOBRAMYCIN; UNINDEXED DRUG; UREIDOPENICILLIN DERIVATIVE;

ARTICLE; BACTEREMIA; CANDIDIASIS; CLINICAL TRIAL; DRUG MIXTURE; GRAM STAINING; HUMAN; HYPOTENSION; MORTALITY; NEPHROTOXICITY; OTOTOXICITY; PNEUMONIA; SEPSIS; SEPTIC SHOCK;

EID: 0034919988     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00003796     Document Type: Article

References (104)

1. Septic shock
2. Treating patients with severe sepsis
3. Septic shock
4. The ACCP-SCCM consensus conference on sepsis and organ failure
5. Sepsis syndrome
6. Antibiotic therapy for gram-negative bacteremia
7. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America
8. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled multicenter trial
9. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial
10. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment
11. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis
12. Bacteremia and severe sepsis in adults: A multicenter prospective survey in ICUs and wards of 24 hospitals. French Bacteremia-Sepsis Study Group
13. INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis
14. Epidemiology of sepsis syndrome in 8 academic medical centers. Academic Medical Center Consortium Sepsis Project Working Group
15. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients
16. Rules of evidence and clinical recommendations on the use of antithrombotic agents
17. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis
18. Factors affecting mortality of gram-negative rod bacteremia
19. The importance of underlying disease in patients with gram-negative bacteremia
20. Effectiveness of betamethasone in management of severe infections. A double-blind study
21. Gram negative bacteremia
22. Steroids in the treatment of clinical septic shock
23. Gram-negative rod bacteremia: Microbiologic, immunologic, and therapeutic considerations
24. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial
25. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORA-SEPT II Study Group
26. Pilot clinical trial of an anti-TNF alpha monoclonal antibody for the treatment of septic shock
27. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group
28. CDP571, a humanized antibody to human tumor necrosis factor-alpha: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group
29. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group
30. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized, double-blind, placebo-controlled trial
31. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein
32. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group
33. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial
34. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study
35. Clinical safety, tolerability, and pharmacokinetics of murine monoclonal antibody to human tumor necrosis factor-α
36. Microbiologic findings and correlations with serum tumor necrosis factor-alpha in patients with severe sepsis and septic shock
37. Nosocomial blood-stream infections in United States hospitals: A three-year analysis
38. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic
39. Prostacyclin and thromboxane A2 formation is increased in human sepsis syndrome. Effects of cyclooxygenase inhibition
40. The effects of ibuprofen on the physiology and survival of patients with sepsis
41. Effect of ibuprofen in patients with severe sepsis: A randomized, double-blind, multicenter study. The Ibuprofen Study Group
42. Carbenicillin plus cefazolin with or without mecillinam as an early treatment of bacteremia caused by gram-negative organisms: Randomized double-blind study
43. Has the mortality of septic shock changed with time
44. Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients
45. Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: Incidence, morbidities and outcomes in surgical ICU patients
46. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: Comparison with a control cohort
47. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections
48. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study
49. Candidemia in nonneutropenic critically ill patients: Analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU
50. Immunocompromised animal models for the study of antibiotic combinations
51. Synergistic combinations of antibiotics in gram-negative bacillary infections
52. A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients
53. Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections
54. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. The EORTC International Antimicrobial Therapy Cooperative Group
55. Antimicrobial synergism in the therapy of gram-negative rod bacteremia
56. Significance of antimicrobial synergism for the outcome of gram negative sepsis
57. Comparative studies of ticarcillin and mezlocillin plus sisomicin in Gram-negative bacillary bacteraemia and bronchopneumonia
58. Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia
59. Addition of rifampin to combination antibiotic therapy for Pseudomonas aeruginosa bacteremia: Prospective trial using the Zelen protocol
60. Stratified outcome comparison of clindamycin-gentamicin vs chloramphenicol-gentamicin for treatment of intra-abdominal sepsis
61. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in non-neutropenic patients
62. Prospective, randomized, controlled study of imipenem-cilastatin versus cefotaxime-amikacin in the treatment of lower respiratory tract infection and septicemia at intensive care units
63. Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group
64. Safety and efficacy of meropenem in patients with septicaemia: A randomised comparison with ceftazidime, alone or combined with amikacin
65. A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients
66. Comparison of the efficacy of cefotaxime alone and the combination cefazolin-tobramycin in the treatment of enterobacterial septicemia
67. Initial treatment of sepsis in non-neutropenic patients: Ceftazidime alone versus 'best guess' combined antibiotic therapy
68. Moxalactam therapy vs. standard antimicrobial therapy for selected serious infections
69. Halving of mortality of severe melioidosis by ceftazidime
70. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections
71. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group
72. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis
73. Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections
74. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. The Piperacillin/Tazobactam Intra-Abdominal Infection Study Group
75. Randomized trial using piperacillin versus ampicillin and amikacin for treatment of premature neonates with risk factors for sepsis
76. Clinical experience with aztreonam in the treatment of gram-negative bacteremia
77. Comparative clinical evaluation of aztreonam versus aminoglycosides in gram-negative septicaemia
78. A multicenter comparative trial of aztreonam in the treatment of gram-negative infections in compromised intensive-care patients
79. Treatment of CAPD-related peritonitis with ciprofloxacin: Results after seven years
80. Empirical antibiotic treatment of sepsis in non-neutropenic patients: Single agent or combination therapy?
81. Intravenous and oral mono- or Combination-therapy in the treatment of severe infections: Ciprofloxacin versus standard antibiotic therapy
82. Controlled comparison of amikacin and gentamicin
83. Prospective comparative study of efficacy and toxicity of netilmicin and amikacin
84. Efficacy of cefpirome in the treatment of septicaemia
85. Randomized comparative trial of cefpirome versus ceftazidime in the empirical treatment of suspected bacteraemia or sepsis. Multicentre Study Group
86. Randomized comparison of cefepime and ceftazidime for treatment of hospitalized patients with gram-negative bacteremia
87. Comparative clinical trial of ceftazidime and imipenem/cilastatin in patients with severe nosocomial pneumonias and septicaemias
88. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients
89. Empiric therapy for infections in the febrile, neutropenic, compromised host
90. Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia
91. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia
92. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System
93. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990
94. Opportunistic candidiasis: An epidemic of the 1980s
95. Candidemia in a tertiary care hospital: Epidemiology, risk factors, and predictors of mortality
96. Nosocomial candidemia: Risk factors and attributable mortality
97. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee
98. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute
99. National epidemiology of mycoses survey (NEMIS): Variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units
100. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group
101. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: A matched cohort study
102. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: A prospective randomized trial
103. Treatment of Candida albicans fungaemia with fluconazole